Experimental Hematology
Volume 27, Issue 12 , Pages 1724-1734 , December 1999

A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans

  • Graham Molineux

      Affiliations

    • Departments of Pharmacology, Pharmaceutics and Clinical Development, Amgen Inc., Thousand Oaks, CA USA
    • Corresponding Author InformationOffprint requests to: Graham Molineux, Amgen Center, Mailstop 15-2-A, One Amgen Center Drive, Thousand Oaks, CA 91320
    • ,
  • Olaf Kinstler

      Affiliations

    • Departments of Pharmacology, Pharmaceutics and Clinical Development, Amgen Inc., Thousand Oaks, CA USA
    • ,
  • Bob Briddell

      Affiliations

    • Departments of Pharmacology, Pharmaceutics and Clinical Development, Amgen Inc., Thousand Oaks, CA USA
    • ,
  • Cynthia Hartley

      Affiliations

    • Departments of Pharmacology, Pharmaceutics and Clinical Development, Amgen Inc., Thousand Oaks, CA USA
    • ,
  • Patricia McElroy

      Affiliations

    • Departments of Pharmacology, Pharmaceutics and Clinical Development, Amgen Inc., Thousand Oaks, CA USA
    • ,
  • Patrick Kerzic

      Affiliations

    • Departments of Pharmacology, Pharmaceutics and Clinical Development, Amgen Inc., Thousand Oaks, CA USA
    • ,
  • Weston Sutherland

      Affiliations

    • Departments of Pharmacology, Pharmaceutics and Clinical Development, Amgen Inc., Thousand Oaks, CA USA
    • ,
  • Greg Stoney

      Affiliations

    • Departments of Pharmacology, Pharmaceutics and Clinical Development, Amgen Inc., Thousand Oaks, CA USA
    • ,
  • Brent Kern

      Affiliations

    • Departments of Pharmacology, Pharmaceutics and Clinical Development, Amgen Inc., Thousand Oaks, CA USA
    • ,
  • Frederick A. Fletcher

      Affiliations

    • Departments of Pharmacology, Pharmaceutics and Clinical Development, Amgen Inc., Thousand Oaks, CA USA
    • ,
  • Art Cohen

      Affiliations

    • Departments of Pharmacology, Pharmaceutics and Clinical Development, Amgen Inc., Thousand Oaks, CA USA
    • ,
  • Elliot Korach

      Affiliations

    • Departments of Pharmacology, Pharmaceutics and Clinical Development, Amgen Inc., Thousand Oaks, CA USA
    • ,
  • Tom Ulich

      Affiliations

    • Departments of Pharmacology, Pharmaceutics and Clinical Development, Amgen Inc., Thousand Oaks, CA USA
    • ,
  • Ian McNiece

      Affiliations

    • University Hospital, Bone Marrow Transplant Program, Denver, CO USA
    • ,
  • Pamela Lockbaum

      Affiliations

    • Departments of Pharmacology, Pharmaceutics and Clinical Development, Amgen Inc., Thousand Oaks, CA USA
    • ,
  • Mary Ann Miller-Messana

      Affiliations

    • Departments of Pharmacology, Pharmaceutics and Clinical Development, Amgen Inc., Thousand Oaks, CA USA
    • ,
  • Sheila Gardner

      Affiliations

    • Departments of Pharmacology, Pharmaceutics and Clinical Development, Amgen Inc., Thousand Oaks, CA USA
    • ,
  • Thomas Hunt

      Affiliations

    • PPD Pharmaco, Austin, TX USA
    • ,
  • Gisela Schwab

      Affiliations

    • Departments of Pharmacology, Pharmaceutics and Clinical Development, Amgen Inc., Thousand Oaks, CA USA

Received 23 March 1999 ,Revised 27 July 1999 ,Accepted 3 August 1999.

References 

  1. Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G (1996) Filgrastim (r-metHuG-CSF): the first 10 years. Blood 88:1907
  2. Bronchud MH, Scarffe JH, Thatcher N, Crowther D, Souza LM, Alton NK, et al. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer. 1987;56:809
  3. Ulich TR, del Castillo J, Souza L. Kinetics and mechanisms of recombinant human granulocyte-colony stimulating factor-induced neutrophilia. Am J Pathol. 1988;133:630
  4. Tanaka H, Kaneko T. Pharmacokinetics of recombinant human granulocyte colony-stimulating factor in the rat. Single and multiple dosing studies. Drug Metab Dispos. 1991;19:200
  5. Roskos L, Cheung EN, Vincent M, Foote MA, Morstyn G. Pharmacology of filgrastim (r-metHuG-CSF). In:  Morstyn G,  Dexter TM,  Foote MA editor. Filgrastim in clinical practice. 2nd edition. New York: Marcel Dekker; 1998;p. 51
  6. Tanaka H, Satake-Ishikawa R, Ishikawa M, Matsuki S, Asano K. Pharmacokinetics of recombinant human granulocyte colony-stimulating factor conjugated to poly(ethylene glycol) in rats. Cancer Res. 1991;51:3710
  7. Delgado C, Francis GE, Fisher D (1992) The uses and properties of PEG-linked proteins.
  8. (1998) In: G Morstyn, TM Dexter, MA Foote (eds) Filgrastim in clinical practice, 2nd edition. New York: Marcel Dekker.
  9. Molineux G, Pojda Z, Dexter TM. A comparison of hematopoiesis in normal and splenectomized mice treated with granulocyte colony-stimulating factor. Blood. 1990;75:563
  10. Welte K, Bonilla MA, Gillio AP, Gabrilove JL, O'Reilly RJ, Souza LM. Recombinant human granulocyte-colony stimulating factor (in vivo effects on myelopoiesis in primates). Behring Inst Mitt. 1988;83:102
  11. Molineux G, Hartley C, McCrea C, McElroy T, McNiece IK. Continuous subcutaneous infusion of hematopoietic growth factors in mice. Exper Hematol. 1995;23:880
  12. Schwab G, Roskos L, Molineux G, Briddell R, Yang BB, Cheung E, et al. A phase I study of sustained-duration filgrastim in normal volunteers. Exper Hematol. 1998;26:709
  13. Roskos L, Yang B, Schwab G, Lockbaum P, Molineux G, Khoo K, et al. A cytokinetic model describes the granulopoietic effects of r-metHuG-CSF-SD/01 (SD/01) and the homeostatic regulation of SD/01 clearance in normal volunteers. Clin Pharmacol Ther. 1999;65:196
  14. Cheung EN, Cosenza M, Lopez O, Hayashi M, Wariner G, Roskos LK. Modelling of r-metHuG-CSF-SD/01 (SD/01) mediated granulopoiesis in normal animals with mathematical extrapolation to neutropenic settings. Blood. 1998;92(Suppl 1):379A
  15. Roskos LK, Yank B, Schwab G, Lockbaum P, Molineux G, Johnston E, et al. Cytokinetic model of rmethHuG-CSF-SD/01 (SD/01) mediated granulopoiesis and the and the “self-regulation” of SD/01 elimination in non-small cell lung cancer (NSCLC). Blood. 1998;92(Suppl):507A
  16. Mast J, Salvesen G, Schnebli HP, Pizzo SV. Evaluation of the rapid plasma elimination of recombinant alpha1-proteinase (synthesis of poly(ethylene glycol) conjugates with improved therapeutic potential). J Lab Clin Med. 1990;116:58
  17. Tanaka H, Tokiwa T. Influence of renal and hepatic failure on the pharmacokinetics of recombinant human granulocyte colony-stimulating factor (KRN8601) in the rat. Cancer Res. 1990;50:6615
  18. Molineux G, Hartley C, McElroy P, McCrea C, McNiece IK. Megakaryocyte growth and development factor accelerates platelet recovery in peripheral blood progenitor cell transplant recipients. Blood. 1996;88:366
  19. Molineux G, Hartley C, McElroy P, McCrea C, Kerzic P, McNiece I. An analysis of the effects of combined treatment with rmGM-CSF and PEG-rHuMGDF in murine bone marrow transplant recipients. Stem Cells. 1997;15:43
  20. de Haan G, Engel C, Dontje B, Nijhof W, Loeffler M. Mutual inhibition of murine erythropoiesis and granulopoiesis during combined erythropoietin, granulocyte colony-stimulating factor, and stem cell factor administration (in vivo interactions and dose-response surfaces). Blood. 1994;84:4157
  21. Molineux G, Hartley C, McElroy P, McNiece I. An analysis of the effects of combined treatment with rmGM-CSF and PEG-rHuMGDF in murine bone marrow transplant recipients. Stem Cells. 1997;15:1
  22. Molineux G, Poida Z, Hampson IN, Lord BI, Dexter TM. Transplantation potential of peripheral blood stem cells induced by granulocyte colony-stimulating factor. Blood. 1990;76:2153
  23. Lane TA, Ho AD, Bashey A, Peterson S, Young D, Law P. Mobilization of blood-derived stem and progenitor cells in normal subjects by granulocyte-macrophage- and granulocyte-colony-stimulating factors. Transplantation. 1999;39:39
  24. Baumann I, Swindell R, Van Hoeff ME, Dexter TM, de Wynter E, Lange C, et al. Mobilisation kinetics of primitive haemopoietic cells following G-CSF with or without chemotherapy for advanced breast cancer. Ann Oncol. 1996;7:1051
  25. Lord BI, Testa NG, Bretti S, Chang J, Demuynck H, Coutinho L, et al. Haemopoietic progenitor and myeloid cell kinetics in humans treated with interleukin-3 and granulocyte/macrophage colony-stimulating factor in combination. Int J Cancer. 1994;59:483
  26. Lord BI, Molineux G, Pojda Z, Souza LM, Mermod JJ, Dexter TM. Myeloid cell kinetics in mice treated with recombinant interleukin-3,granulocyte colony-stimulating factor (CSF), or granulocyte-macrophage CSF in vivo. Blood. 1991;77:2154
  27. Capdeville R, Xu Z-X, Faugeas O, Schulz R, Oberling F, Platzer E. A single injection of RO 25-8315, a long-acting pegylated G-CSF mutein, is safe and effective in mobilizing peripheral blood progenitor cells (PBPC) in healthy volunteers. A clinical pharmacology phase I study. Bone Marrow Transplant. 1997;19(Suppl 1):S12
  28. Xu Z-X, Capdeville R, Faugeas O, Oberling F, Platzer E. Safety/tolerability and pharmacokinetics/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of a long-acting (5-7 days), chemically modified G-CSF mutein (Ro 25-8315) to healthy subjects. Proc ASCO. 1997;16:87a
  29. Farese AM, Roskos L, Cheung E, Stead RB, Yin SM, Macvittie TJ. A single administration of r-metHuG-CSF-SD/01 (SD/01) significantly improves neutrophil recovery following autologous bone marrow transplantation. Blood. 1998;92(Suppl.):112A

PII: S0301-472X(99)00112-5

Experimental Hematology
Volume 27, Issue 12 , Pages 1724-1734 , December 1999

Article Tools

* Image Usage & Resolution